Meeting
2012 ASCO Annual Meeting
Estrogen receptor in HER2-positive early breast cancer: Two different diseases?
Authors
Eva Maria Ciruelos Gil
Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
Eva Maria Ciruelos Gil , Ismael Ghanem , Luis Manso , Sergio Hoyos , Carlos Castañeda , David Lora , Cesar Mendiola Sr., Blanca Sancho , Tomas Pascual , Hernan Cortes-Funes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 30, 2012 (suppl; abstr 642)
DOI
10.1200/jco.2012.30.15_suppl.642
Abstract #
642
Poster Bd #
14E
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population-based cancer registry study.
First Author: Antonino Musolino
Poster
2014 ASCO Annual Meeting
A multicenter randomized study comparing 6 versus 12 months of trastuzumab in combination with dose-dense docetaxel following FEC as adjuvant treatment of women with axillary-node–positive or high-risk, node-negative breast cancer overexpressing HER2.
First Author: Dimitrios Mavroudis
Poster
2011 ASCO Annual Meeting
Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment (adj TX) for patients with early breast cancer (EBC).
First Author: P. Ravdin
First Author: Natália Polidorio